Genomic Health starts IPO price talk at $12-$14 per share

By Ted A. Knutson

Washington, Sept. 9 - Genomic Health, Inc. started the price talk for its planned initial public offering of 5.02 million common shares at $12 to $14 per share.

The offering includes an over-allotment option for up to 753,000 shares.

The announcement came in an amendment to the company's S-1 registration statement with the Securities and Exchange Commission.

JPMorgan and Lehman Brothers are the joint bookrunning managers for the sale. The other underwriters are Piper Jaffray, Thomas Weisel Partners and JMP Securities.

Genomic Health estimated net proceeds from the offering to the company at $58.6 million to $67.7 million.

The Redwood City, Calif.-based company is developing genomic-based clinical diagnostic tests for cancer.

The company hopes to be listed on the Nasdaq under the ticker symbol "GHDX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.